Literature DB >> 23406896

Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.

Dhaval K Shah1, Alison M Betts.   

Abstract

Tissue vs. plasma concentration profiles have been generated from a physiologically-based pharmacokinetic model of monoclonal antibody (mAb). Based on the profiles, we hypothesized that a linear relationship between the plasma and tissue concentrations of non-binding mAbs could exist; and that the relationship may be generally constant irrespective of the absolute mAb concentration, time, and animal species being analyzed. The hypothesis was verified for various tissues in mice, rat, monkey, and human using mAb or antibody-drug conjugate tissue distribution data collected from diverse literature. The relationship between the plasma and various tissue concentrations was mathematically characterized using the antibody biodistribution coefficient (ABC). Estimated ABC values suggest that typically the concentration of mAb in lung is 14.9%, heart 10.2%, kidney 13.7%, muscle 3.97%, skin 15.7%, small intestine 5.22%, large intestine 5.03%, spleen 12.8%, liver 12.1%, bone 7.27%, stomach 4.98%, lymph node 8.46%, adipose 4.78%, brain 0.351%, pancreas 6.4%, testes 5.88%, thyroid 67.5% and thymus is 6.62% of the plasma concentration. The validity of using the ABC to predict mAb concentrations in different tissues of mouse, rat, monkey, and human species was evaluated by generating validation data sets, which demonstrated that predicted concentrations were within 2-fold of the observed concentrations. The use of ABC to infer tissue concentrations of mAbs and related molecules provides a valuable tool for investigating preclinical or clinical disposition of these molecules. It can also help eliminate or optimize biodistribution studies, and interpret efficacy or toxicity of the drug in a particular tissue.

Entities:  

Keywords:  ABC; ADC; Antibody Drug Conjugates; Antibody biodistribution coefficient; Monoclonal antibody; Tissue distribution; Tissue vs. plasma concentration

Mesh:

Substances:

Year:  2013        PMID: 23406896      PMCID: PMC3893240          DOI: 10.4161/mabs.23684

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  33 in total

1.  Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier.

Authors:  Y Zhang; W M Pardridge
Journal:  J Neuroimmunol       Date:  2001-03-01       Impact factor: 3.478

2.  Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting.

Authors:  S M Danilov; V D Gavrilyuk; F E Franke; K Pauls; D W Harshaw; T D McDonald; D J Miletich; V R Muzykantov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-06       Impact factor: 5.464

Review 3.  Antibody pharmacokinetics and pharmacodynamics.

Authors:  Evelyn D Lobo; Ryan J Hansen; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2004-11       Impact factor: 3.534

4.  Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats.

Authors:  C Tanaka; R Kawai; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

5.  Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.

Authors:  Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Addy C M van de Luijtgaarden; Janneke D M Molkenboer-Kuenen; Sandra Heskamp; Melissa H S Roeffen; Hanneke W M van Laarhoven; Peter J Houghton; Wim J G Oyen; Otto C Boerman; Winette T A van der Graaf
Journal:  Clin Cancer Res       Date:  2011-10-28       Impact factor: 12.531

6.  Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration.

Authors:  R Blake Pepinsky; Zhaohui Shao; Benxiu Ji; Qin Wang; Gym Meng; Lee Walus; Xinhua Lee; Yinghui Hu; Christilyn Graff; Ellen Garber; Werner Meier; Sha Mi
Journal:  J Pharmacol Exp Ther       Date:  2011-08-01       Impact factor: 4.030

7.  Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts.

Authors:  Lubna Abuqayyas; Joseph P Balthasar
Journal:  AAPS J       Date:  2012-04-18       Impact factor: 4.009

8.  Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.

Authors:  Adrienne Brouwers; Peter Mulders; Egbert Oosterwijk; Wilhelmina Buijs; Frans Corstens; Otto Boerman; Wim Oyen
Journal:  Cancer Biother Radiopharm       Date:  2004-08       Impact factor: 3.099

9.  Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.

Authors:  Hongsheng Xie; Charlene Audette; Mary Hoffee; John M Lambert; Walter A Blättler
Journal:  J Pharmacol Exp Ther       Date:  2003-11-21       Impact factor: 4.030

10.  Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin.

Authors:  Leslie A Khawli; Myra M Mizokami; Jahangir Sharifi; Peisheng Hu; Alan L Epstein
Journal:  Cancer Biother Radiopharm       Date:  2002-08       Impact factor: 3.099

View more
  73 in total

Review 1.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

2.  Influence of molecular size on tissue distribution of antibody fragments.

Authors:  Zhe Li; Ben-Fillippo Krippendorff; Sharad Sharma; Antje C Walz; Thierry Lavé; Dhaval K Shah
Journal:  MAbs       Date:  2015-10-23       Impact factor: 5.857

Review 3.  Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.

Authors:  S Sadekar; I Figueroa; M Tabrizi
Journal:  AAPS J       Date:  2015-05-02       Impact factor: 4.009

Review 4.  Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.

Authors:  Aman P Singh; Young G Shin; Dhaval K Shah
Journal:  Pharm Res       Date:  2015-02-11       Impact factor: 4.200

5.  Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats.

Authors:  Xi Chen; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2015-04-01       Impact factor: 3.922

6.  Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.

Authors:  Sameed Ahmed; Miandra Ellis; Hongshan Li; Luca Pallucchini; Andrew M Stein
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-29       Impact factor: 2.745

7.  Quantification of IgG monoclonal antibody clearance in tissues.

Authors:  Miro J Eigenmann; Ludivine Fronton; Hans Peter Grimm; Michael B Otteneder; Ben-Fillippo Krippendorff
Journal:  MAbs       Date:  2017-06-14       Impact factor: 5.857

8.  Impact of altered endogenous IgG on unspecific mAb clearance.

Authors:  Saskia Fuhrmann; Charlotte Kloft; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-24       Impact factor: 2.745

9.  Peptide-based PET quantifies target engagement of PD-L1 therapeutics.

Authors:  Dhiraj Kumar; Ala Lisok; Elyes Dahmane; Matthew McCoy; Sagar Shelake; Samit Chatterjee; Viola Allaj; Polina Sysa-Shah; Bryan Wharram; Wojciech G Lesniak; Ellen Tully; Edward Gabrielson; Elizabeth M Jaffee; John T Poirier; Charles M Rudin; Jogarao Vs Gobburu; Martin G Pomper; Sridhar Nimmagadda
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

10.  Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.

Authors:  Jamie Campbell; Josquin Nys; Laura Eghobamien; E Suzanne Cohen; Matthew J Robinson; Matthew A Sleeman
Journal:  MAbs       Date:  2016-08-12       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.